Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Serratia : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
References

Related Articles
Enterobacter Infections

Escherichia Coli Infections

Klebsiella Infections

Meningitis

Pneumonia, Bacterial

Proteus Infections

Providencia Infections

Sepsis, Bacterial




Patient Education
Click here for patient education.



Author: Basilio J Anía, MD, Consultant in Internal Medicine, Associate Professor of Infectious Diseases, Department of Internal Medicine, Division of Infectious Diseases, Hospital Negrín & Universidad de Las Palmas de Gran Canaria, Spain

Editors: Thomas Herchline, MD, Associate Professor of Medicine, Wright State University Boonshoft School of Medicine; Medical Director, Combined Health District of Montgomery County, Ohio; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; John L Brusch, MD, FACP, Assistant Professor of Medicine, Harvard Medical School; Consulting Staff, Department of Medicine and Infectious Disease Service, Cambridge Health Alliance; Eleftherios Mylonakis, MD, Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital; Burke A Cunha, MD, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Author and Editor Disclosure

Synonyms and related keywords: Serratia marcescens, S marcescens, Serratia plymuthica, S plymuthica, Serratia liquefaciens, S liquefaciens, Serratia rubidaea, S rubidaea, Serratia odoriferae, S odoriferae, sepsis, Serratia infection, urinary tract infection, UTI, respiratory tract instrumentation, meningitis, cerebral abscess, bacterial keratitis, bacterial parotitis

Background

Serratia are opportunistic gram-negative bacteria classified in the tribe Klebsielleae and the large family Enterobacteriaceae.

Serratia marcescens is the only pathogenic species of Serratia, except for rare reports of disease resulting from infection with Serratia plymuthica, Serratia liquefaciens, Serratia rubidaea, and Serratia odorifera.

Some strains of S marcescens are capable of producing a pigment called prodigiosin, which ranges in color from dark red to pale pink, depending on the age of the colonies. S marcescens has a predilection for growth on starchy foodstuffs, where the pigmented colonies are easily mistaken for drops of blood.

In 1819, Bartolomeo Bizio, a pharmacist from Padua, Italy, discovered and named S marcescens when he identified the bacterium as the cause of a miraculous bloody discoloration in a cornmeal mush called polenta. Bizio named Serratia in honor of an Italian physicist named Serrati, who invented the steamboat, and Bizio chose marcescens from the Latin word for decaying because the bloody pigment was found to deteriorate quickly.

Since 1906, physicians have used S marcescens as a biological marker for studying the transmission of microorganisms, because until the 1950s, this bacterium generally was considered a harmless saprophyte. Only since the 1960s has S marcescens been recognized as an opportunistic human pathogen.

Pathophysiology

In the hospital, Serratia tends to colonize the respiratory and urinary tracts of adults, rather than the gastrointestinal tract.

Serratia causes about 2% of nosocomial infections of the bloodstream, lower respiratory tract, urinary tract, surgical wounds, and skin and soft tissues of adult patients. Outbreaks of S marcescens meningitis, wound infections, and arthritis have occurred in pediatric wards.

Serratia has caused endocarditis and osteomyelitis in people addicted to heroin.

Cases of arthritis resulting from Serratia infection are reported in outpatients who have received intraarticular injections.

Frequency

United States

Serratia species cause 1.4% of nosocomial bloodstream infections.

International

The prevalence of Serratia in nosocomial infections is diminishing, but these bacteria still are able to cause hospital outbreaks, especially in intensive care units.

Mortality/Morbidity

  • Crude mortality for nosocomial bloodstream infection with Serratia is 26%.
  • Mortality is high in patients with meningitis and endocarditis caused by Serratia infection.

Age

Outbreaks occur in neonates and infants. In adults, most cases are isolated, but occasional nosocomial outbreaks occur.



History

  • Patients with Serratia sepsis may present with fever, chills, shock, and respiratory distress.
  • Urinary tract infection
    • Approximately 30-50% of patients are asymptomatic. When symptoms are present, patients may have fever, frequent urination, dysuria, pyuria, or pain upon urination.
    • In 90% of cases, patients have a history of recent surgery or instrumentation of the urinary tract.
    • Important risk factors include diabetes mellitus, urinary tract obstruction, and renal failure.
  • Respiratory tract infection
    • These patients usually are colonized with Serratia after instrumentation (eg, ventilation, bronchoscopy), especially those patients with chronic obstructive pulmonary disease.
    • Patients may have pneumonia, but this development is rare. If pneumonia develops, patients may have fever, chills, productive cough (sometimes with pseudohemoptysis), hypotension, dyspnea, or chest pain.
  • Meningitis or cerebral abscess
    • Meningitis or cerebral abscesses resulting from Serratia infection may develop in premature children and neonates with prior sepsis. Patients who have experienced head trauma or have undergone neurosurgery, lumbar puncture, or even epidural injections are at risk of developing meningitis or cerebral abscess.
    • The symptoms are those of gram-negative meningitis (eg, headache, fever, vomiting, stupor, coma).
  • Patients with intraabdominal infections resulting from Serratia infection may present with biliary drainage, hepatic abscess, pancreatic abscess, and peritoneal exudate.
  • Patients with Serratia infection may have osteomyelitis or arthritis, which can be hematogenous in people addicted to intravenous drugs or may be caused exogenously by surgery, open trauma, or intraarticular injection.
  • Patients with endocarditis resulting from Serratia infection may present with fever, petechiae, and, occasionally, embolic complications (eg, stroke, arterial emboli).
  • Patients with Serratia-related ocular infections will have keratitis or endophthalmitis.
  • Patients with soft tissue infections resulting from Serratia may have surgical scars, cellulitis, phlebitis, or skin infections.
  • Patients with Serratia-related otitis media have earaches, hearing loss, and ear discharge.
  • Bacterial parotitis associated with Serratia infection is rare.

Physical

  • Pink hypopyon in the absence of hyphema may suggest S marcescens endophthalmitis.

Causes

  • Sepsis or bacteremia
    • The main risk factor is hospitalization. Placement of intravenous, intraperitoneal, or urinary catheters and prior instrumentation of the respiratory tract have been identified as risk factors for inpatients.
    • Other risk factors include cardiac valve replacement, transfusions, and the use of contaminated intravenous infusions. An outbreak of bacteremia was caused by pooling the residual contents of preservative-free epoetin vials for later use. Another outbreak was traced to tampering with an infused narcotic by a hospital employee. In addition, 2 cases of bacteremia during an outbreak of S marcescens infections were traced to contamination of a faucet in an intensive care unit.
  • Urinary tract infection
    • In 90% of cases, patients have a history of recent surgery or instrumentation of the urinary tract.
    • Important risk factors are diabetes mellitus, urinary tract obstruction, and renal failure.
  • Respiratory tract colonization appears after instrumentation (eg, ventilation, bronchoscopy), especially in patients with chronic obstructive pulmonary disease. During an outbreak of S marcescens infections traced to a contaminated faucet (including consumption of tap water from the faucet) in an intensive care unit, 9 patients developed respiratory tract colonization: septic bronchitis in 8 and empyema in 1.
  • Meningitis or cerebral abscess may result from Serratia infection in premature children and neonates with prior sepsis. Meningitis can also develop in adults who have experienced head trauma or have undergone neurosurgery, epidural injection, or lumbar puncture.
  • Osteomyelitis or arthritis can be hematogenous in people addicted to intravenous drugs or can be caused exogenously by surgery, open trauma, or intraarticular injection.
  • Ocular infections
    • Serratia infection frequently causes nonulcerating bacterial keratitis, which is associated with soft and rigid contact lens wear.
    • Endophthalmitis usually occurs after eye surgery.
  • Bacterial parotitis can appear in individuals with prior sialectasia.
  • Dermal abscesses and skin ulcers in the legs have appeared after a toe-web infection.



Enterobacter Infections
Escherichia Coli Infections
Klebsiella Infections
Meningitis
Pneumonia, Bacterial
Proteus Infections
Providencia Infections
Sepsis, Bacterial


Lab Studies

  • CBC count with differential
    • Leukocytosis with neutrophilia
    • Leukopenia (rare)
    • Presence of more than 10% immature neutrophils (ie, bands)
    • Possible anemia
  • Serum biochemistry for glucose, urea, and creatinine
  • Bacterial cultures and antibiograms
    • Blood
    • Urine
    • Samples of abscesses or effusions
    • Catheters suspected of being contaminated
    • Liquid soaps or disinfectants suspected of being contaminated
    • IV fluids suspected of being contaminated
  • Cerebrospinal fluid
    • Polynuclear pleocytosis
    • High protein level
    • Low glucose level

Imaging Studies

  • Perform chest radiography if pneumonia is suspected or in the presence of respiratory distress.
  • Abdominal ultrasonography or computed tomography (CT) scans will rule out obstructive hydronephrosis or intraabdominal abscesses (eg, hepatic, pancreatic, other).
  • Transthoracic or transesophageal echocardiography may reveal valvular vegetations and valvular or paravalvular regurgitation.
  • Perform a spinal CT scan or MRI if spondylitis is suspected.

Procedures

  • Lumbar puncture should be performed in all patients with suspected meningitis. If signs of increased intracranial pressure are present (focal neurologic abnormalities, seizure, or altered mental status), obtain a head CT scan prior to the puncture to exclude cerebral abscess or mass lesion.



Medical Care

Antibiotic therapy is the primary treatment for most patients. Home therapy is an option for patients who are clinically stable.

Surgical Care

Purulent collections (abscesses) may require drainage.

Consultations

  • Consult a cardiac surgeon if considering valve replacement in patients with infective endocarditis.
  • In a possible nosocomial outbreak, strain typing may assist the epidemiologic investigation.



S marcescens is naturally resistant to ampicillin, macrolides, and first-generation cephalosporins. In Taiwan, 92% of the strains are resistant to cefotaxime, but 99% are still susceptible to ceftazidime. Therapy for Serratia infections should include an aminoglycoside in addition to an antipseudomonal beta-lactam, as the single use of a beta-lactam can select for resistant mutants. Most strains are susceptible to amikacin, but reports indicate increasing resistance to gentamicin and tobramycin. Quinolones also are highly active against most strains. Definitive therapy should be based on the results of susceptibility testing because multiresistant strains are common.

Drug Category: Antibiotics

Empiric antimicrobial therapy should cover all likely pathogens in the context of the clinical setting.

Drug NameAmikacin (Amikin)
DescriptionPreferred aminoglycoside. Usually synergistic with antipseudomonal beta-lactams. Use both in combination, pending results of susceptibility testing. For gram-negative bacterial coverage of infections resistant to gentamicin and tobramycin. Effective against Pseudomonas aeruginosa. Irreversibly binds to 30S subunit of bacterial ribosomes. Blocks recognition step in protein synthesis. Causes bacterial growth inhibition.
Adult Dose15 mg/kg/d IV q24h or in a single dose; use adjusted dosing weight, IBW + 0.4 (ABW-IBW), for calculation if actual body weight exceeds IBW by more than 30%
Pediatric DoseAdminister as in adults
ContraindicationsDocumented hypersensitivity
InteractionsCoadministration with other aminoglycosides, penicillins, cephalosporins, and amphotericin B increases nephrotoxicity; enhances effects of neuromuscular blocking agents; causes respiratory depression; irreversible hearing loss may occur with coadministration of loop diuretics
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsNot intended for long-term therapy; caution in patients with renal failure (not on dialysis), hypocalcemia, myasthenia gravis, and conditions that depress neuromuscular transmission

Drug NameAztreonam (Azactam)
DescriptionUsually synergistic with amikacin. Use both in combination, pending results of susceptibility testing. A monobactam that inhibits cell wall synthesis during bacterial growth. Active against gram-negative bacilli.
Adult Dose1-2 g IV q6-8h
Pediatric Dose90-120 mg/kg/d IV/IM divided q6-8h
ContraindicationsDocumented hypersensitivity
InteractionsTetracyclines may reduce effects
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsAdjust dose in renal insufficiency

Drug NameMeropenem (Merrem IV)
DescriptionPreferred therapy for Serratia meningitis. Bactericidal broad-spectrum carbapenem antibiotic that inhibits cell wall synthesis. Effective against most gram-positive and gram-negative bacteria. Has increased activity against gram-negative bacteria and slightly decreased activity against staphylococci and streptococci compared to imipenem.
Adult Dose1000 mg IV q8h
Pediatric Dose40 mg/kg IV q8h
ContraindicationsDocumented hypersensitivity
InteractionsProbenecid may inhibit renal excretion of meropenem, increasing meropenem levels
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsAdjust dosage in patients with renal insufficiency; pseudomembranous colitis and thrombocytopenia may occur, requiring immediate discontinuation of medication

Drug NameImipenem-cilastatin (Primaxin)
DescriptionComparable in activity to meropenem.
Adult DoseBase initial dose on severity of infection and administer in equally divided doses; dose may range from 500-1000 mg IV q6h; not to exceed 4 g/d
Pediatric Dose<12 years: Not established; 15-25 mg/kg/dose IV q6h suggested for > 3 months
>12 years:
Fully susceptible organisms: Not to exceed 2 g/d
Moderately susceptible organisms: Not to exceed 4 g/d
ContraindicationsDocumented hypersensitivity
InteractionsNephrotoxicity increased with aminoglycoside; coadministration with cyclosporine may increase CNS adverse effects of both agents; coadministration with ganciclovir may result in generalized seizures
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsRisk of inducing seizures or cerebral toxicity with 1-g doses; adjust dose in renal insufficiency; avoid use in children <12 y

Drug NameCiprofloxacin (Cipro)
DescriptionGreatest anti-P aeruginosa activity among the quinolones. May be particularly useful for isolates resistant to the aminoglycosides.
Adult Dose400 mg IV q12h
500-750 mg PO q12h
Pediatric Dose<18 years: Not recommended
ContraindicationsDocumented hypersensitivity
InteractionsAntacids, iron salts, and zinc salts may reduce serum levels; administer antacids 2-4 h before or after taking fluoroquinolones; cimetidine may interfere with metabolism of fluoroquinolones; levofloxacin reduces therapeutic effects of phenytoin; probenecid may increase levofloxacin serum concentrations; may increase toxicity of theophylline, caffeine, cyclosporine, and digoxin (monitor digoxin levels); may increase effects of anticoagulants (monitor PT)
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsIn prolonged therapy, perform periodic evaluations of organ system functions (eg, renal, hepatic, hematopoietic); adjust dose in renal function impairment; superinfections may occur with prolonged or repeated antibiotic therapy



Further Inpatient Care

  • Remove or change catheters suspected of being contaminated.

Deterrence/Prevention

  • Avoid reusing single-use vials, and reject possibly contaminated IV fluids.
  • Avoid using soaps or disinfectants that may be contaminated.
  • Use disposable ECG leads.
  • Emphasize standard precautions. Hospital employees should wash their hands before and after contact with patients. The most frequent mechanism of transmission in nosocomial outbreaks is through soiled hands.
  • IV lines should be removed as soon as possible.

Prognosis

  • The mortality rate for severe infection (bacteremia) is 26%. For those who survive, the prognosis for complete recovery is good.
  • Patients with S marcescens endophthalmitis have a poor prognosis for maintaining vision.



Special Concerns

  • If bacterial disease is suspected in a patient who is severely immunocompromised and infected with HIV, consider the diagnosis of Serratia infection.
  • Risk factors for severe infections with Serratia include old age, previous antibiotic treatment, and chronic or debilitating diseases.



  • Alonso Fernandez R, Baquero Mochales F. [The genus Serratia: its biology, clinical effects and epidemiology]. Rev Clin Esp. Apr 1994;194(4):294-9. [Medline].
  • Anonymous. The miracle microbe: Serratia marcescens. [Full Text].
  • Aron M, Goel R, Gupta NP, Seth A. Incidental detection of purulent fluid in kidney at percutaneous nephrolithotomy for branched renal calculi. J Endourol. Mar 2005;19(2):136-9. [Medline].
  • Bosi C, Davin-Regli A, Charrel R, et al. Serratia marcescens nosocomial outbreak due to contamination of hexetidine solution. J Hosp Infect. Jul 1996;33(3):217-24. [Medline].
  • Bruckner DA, Colonna P, Bearson BL. Nomenclature for aerobic and facultative bacteria. Clin Infect Dis. Oct 1999;29(4):713-23. [Medline].
  • Capitano B, Nicolau DP, Potoski BA, et al. Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections. Pharmacotherapy. Jun 2004;24(6):803-7. [Medline].
  • Carrero P, Garrote JA, Pacheco S, et al. Report of six cases of human infection by Serratia plymuthica. J Clin Microbiol. Feb 1995;33(2):275-6. [Medline].
  • Civen R, Vugia DJ, Alexander R. Outbreak of Serratia marcescens infections following injection of betamethasone compounded at a community pharmacy. Clin Infect Dis. Oct 1 2006;43(7):831-7.
  • Cohen SM, Flynn HW Jr, Miller D. Endophthalmitis caused by Serratia marcescens. Ophthalmic Surg Lasers. Mar 1997;28(3):195-200. [Medline].
  • Demetriou CA, Cunha BA. Serratia marcescens bacteremia after carotid endarterectomy and coronary artery bypass grafting. Heart Lung. Jul-Aug 1999;28(4):293-4. [Medline].
  • Dominguez Herrera JM, Jimenez Mejias ME, Infante Cossio P, et al. [Acute bacterial parotitis caused by Serratia marcescens]. Rev Clin Esp. Apr 1996;196(4):271-2. [Medline].
  • Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. Aug 1999;29(2):239-44. [Medline].
  • Edson RS, Terrell CL. The aminoglycosides. Mayo Clin Proc. May 1999;74(5):519-28. [Medline].
  • Eisenstein BI, Zaleznik DF. Enterobacteriaceae. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. Vol 2. Philadelphia, Pa: Churchill Livingstone; 2000:. 2294-2310.
  • Friedman ND, Peterson NB, Sumner WT, Alexander BD. Spontaneous dermal abscesses and ulcers as a result of Serratia marcescens. J Am Acad Dermatol. Aug 2003;49(2 Suppl Case Reports):S193-4. [Medline].
  • Grohskopf LA, Roth VR, Feikin DR, et al. Serratia liquefaciens bloodstream infections from contamination of epoetin alfa at a hemodialysis center. N Engl J Med. May 17 2001;344(20):1491-7. [Medline].
  • Gurevich I, Tafuro PA, Cunha BA. Serratia peritonitis in hemodialysis patients. Clinical Microbiology Newsletter. 1987;9:55-56.
  • Haddy RI, Mann BL, Nadkarni DD, et al. Nosocomial infection in the community hospital: severe infection due to Serratia species. J Fam Pract. Mar 1996;42(3):273-7. [Medline].
  • Hejazi A, Falkiner FR. Serratia marcescens. J Med Microbiol. Nov 1997;46(11):903-12. [Medline].
  • Hellinger WC, Brewer NS. Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Mayo Clin Proc. Apr 1999;74(4):420-34. [Medline].
  • Heltberg O, Skov F, Gerner-Smidt P, et al. Nosocomial epidemic of Serratia marcescens septicemia ascribed to contaminated blood transfusion bags. Transfusion. Mar 1993;33(3):221-7. [Medline].
  • Hertle R, Schwarz H. Serratia marcescens internalization and replication in human bladder epithelial cells. BMC Infect Dis. Jun 9 2004;4(1):16. [Medline].
  • Horcajada JP, Martinez JA, Alcon A. Acquisition of multidrug-resistant Serratia marcescens by critically ill patients who consumed tap water during receipt of oral medication. Infect Control Hosp Epidemiol. Jul 2006;27(7):774-7.
  • Hsieh S, Babl FE. Serratia marcescens cellulitis following an iguana bite. Clin Infect Dis. May 1999;28(5):1181-2. [Medline].
  • Johnson DH, Cunha BA, Klein NC. Serratia. Infect Dis Pract. 1993;17:6-8.
  • Johnson JS, Croall J, Power JS, Armstrong GR. Fatal Serratia marcescens meningitis and myocarditis in a patient with an indwelling urinary catheter. J Clin Pathol. Oct 1998;51(10):789-90. [Medline].
  • Kirschke DL, Jones TF, Craig AS, et al. Pseudomonas aeruginosa and Serratia marcescens contamination associated with a manufacturing defect in bronchoscopes. N Engl J Med. Jan 16 2003;348(3):214-20. [Medline].
  • Manfredi R, Nanetti A, Ferri M, Chiodo F. Clinical and microbiological survey of Serratia marcescens infection during HIV disease. Eur J Clin Microbiol Infect Dis. Apr 2000;19(4):248-53. [Medline].
  • McLeod SD, Goei SL, Taglia DP, McMahon TT. Nonulcerating bacterial keratitis associated with soft and rigid contact lens wear. Ophthalmology. Mar 1998;105(3):517-21. [Medline].
  • Munoz G, Alio JL, Perez-Santonja JJ, et al. Ulcerative keratitis caused by Serratia marcescens after laser in situ keratomileusis. J Cataract Refract Surg. Feb 2004;30(2):507-12. [Medline].
  • Ostrowsky BE, Whitener C, Bredenberg HK, et al. Serratia marcescens bacteremia traced to an infused narcotic. N Engl J Med. May 16 2002;346(20):1529-37. [Medline].
  • Pai HH, Chen WC, Peng CF. Cockroaches as potential vectors of nosocomial infections. Infect Control Hosp Epidemiol. Nov 2004;25(11):979-84. [Medline].
  • Royo P, del Valle O, Boquete T. [Epidemiology of Serratia marcescens between 1987 and 1995 at Vall d''Hebron Hospital]. Enferm Infecc Microbiol Clin. Dec 1997;15(10):519-27. [Medline].
  • Sehdev PS, Donnenberg MS. Arcanum: The 19th-century Italian pharmacist pictured here was the first to characterize what are now known to be bacteria of the genus Serratia. Clin Infect Dis. Oct 1999;29(4):770, 925. [Medline].
  • Shih HI, Lee HC, Lee NY. Serratia marcescens bacteremia at a medical center in southern Taiwan: high prevalence of cefotaxime resistance. J Microbiol Immunol Infect. Oct 2005;38(5):350-7.
  • Sickbert-Bennett EE, Weber DJ, Gergen-Teague MF, et al. Comparative efficacy of hand hygiene agents in the reduction of bacteria and viruses. Am J Infect Control. Mar 2005;33(2):67-77. [Medline].
  • Sokalski SJ, Jewell MA, Asmus-Shillington AC, et al. An outbreak of Serratia marcescens in 14 adult cardiac surgical patients associated with 12-lead electrocardiogram bulbs. Arch Intern Med. Apr 1992;152(4):841-4. [Medline].
  • Tanaka T, Takahashi H, Kobayashi JM, et al. A nosocomial outbreak of febrile bloodstream infection caused by heparinized-saline contaminated with Serratia marcescens, Tokyo, 2002. Jpn J Infect Dis. Oct 2004;57(5):189-92. [Medline].
  • Ursua PR, Unzaga MJ, Melero P, et al. Serratia rubidaea as an invasive pathogen. J Clin Microbiol. Jan 1996;34(1):216-7. [Medline].
  • Weinstein RA. Lessons from an epidemic, again. N Engl J Med. May 17 2001;344(20):1544-5. [Medline].
  • Yannelli B, Schoch PA, Cunha BA. Serratia infections in the hospital. Clinical Microbiology Newsletter. 1987;9:157-160.
  • Yu VL. Serratia marcescens: historical perspective and clinical review. N Engl J Med. Apr 19 1979;300(16):887-93. [Medline].
  • al Hazzaa SA, Tabbara KF, Gammon JA. Pink hypopyon: a sign of Serratia marcescens endophthalmitis. Br J Ophthalmol. Dec 1992;76(12):764-5. [Medline].
  • van der Vorm ER, Woldring-Zwaan C. Source, carriers, and management of a Serratia marcescens outbreak on a pulmonary unit. J Hosp Infect. Dec 2002;52(4):263-7. [Medline].

Serratia excerpt

Article Last Updated: Jan 29, 2007